References
1. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. JAMA. 2017;317(17):1774-84.
2. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program. Mayo Clin Proc. 2016;91(1):84-96.
3. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database. Neurology. 2019;92(21):1006-13.
4. Inoue K, Figueroa JF, DeJong C, Tsugawa Y, Orav EJ, Shen C, Kazi DS. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. Circulation: Cardiovascular Quality and Outcomes. 2021;14(5):e007521.
5. Murayama A. Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States. International Journal of Rheumatic Diseases. 2023;n/a(n/a).
6. Murayama A. Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma. J Allergy Clin Immunol Pract. 2023;11(9):2916-8.
7. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg. 2022;166(5):869-76.
8. Murayama A, Yamada K, Yoshida M, Kaneda Y, Saito H, Sawano T, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol. 2022;17(6):819-26.
9. Nejstgaard CH, Bero L, Hrobjartsson A, Jorgensen AW, Jorgensen KJ, Le M, Lundh A. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ. 2020;371:m4234.
10. Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356(4):331-3.
11. Anderson TS, Krieger MS, Marshall BDL, Cerdá M, Hadland S. Financial Payments to Teaching Hospitals by Companies Marketing Opioids. J Gen Intern Med. 2020;35(10):3108-10.
12. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T. Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan. JAMA Netw Open. 2019;2(5):e193817.
13. Murata N, Ozaki A, Murayama A, Sawano T, Tanimoto T. The Diovan scandal in Japan; don’t let bygones be bygones. J Hum Hypertens. 2022;36(5):500-1.
14. Ozaki A, Saito H, Senoo Y, Sawano T, Shimada Y, Kobashi Y, et al. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016. Health Policy. 2020;124(7):727-35.
15. Murayama A, Shigeta H, Kamamoto S, Yamashita E, Saito H, Sawano T, et al. Pharmaceutical Payments to Japanese Board-Certified Head and Neck Surgeons Between 2016 and 2019. OTO Open. 2023;7(1):e31.
16. Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, et al. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019. Int J Environ Res Public Health. 2022;19(12):7417.
17. Murayama A, Hoshi M, Saito H, Kamamoto S, Tanaka M, Kawashima M, et al. Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019. Respiration. 2022;101(12):1088-98.
18. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54.
19. Kamamoto S, Murayama A, Kusumi E, Yoshida M, Saito H, Sawano T, et al. Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross-sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019. Pediatr Blood Cancer. 2022;69(10):e29891.
20. Murayama A, Saito H, Kamamoto S, Shigeta H, Yamashita E, Tanimoto T, Ozaki A. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019. Int Urogynecol J. 2023;34(6):1285-92.
21. Murayama A, Mamada H, Shigeta H, Yoshinaga T, Saito H, Yamashita E, et al. Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019. J Clin Rheumatol. 2023;29(3):118-25.
22. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Sci Rep. 2023;13(1):7425.
23. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. BMJ Open. 2023;13(4):e068237.
24. Murayama A. Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan. Cureus. 2023;15(10):e46650.
25. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020. J Eval Clin Pract. 2023;29(6):883-6.
26. Murayama A, Kamamoto S, Murata N, Yamasaki R, Yamada K, Yamashita E, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023;38(4):565-73.
27. Mamada H, Murayama A, Kamamoto S, Kaneda Y, Yoshida M, Sugiura S, et al. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate in Japan and the United States. Arthritis Care Res (Hoboken). 2023;75(6):1278-86.
28. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T, Akihiko O. Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus. 2022;35(10).
29. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J. 2021;32(2):443-51.
30. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect. 2022;28(3):460-2.
31. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et al. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy. 2021;125(3):320-6.
32. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver Int. 2021;41(3):464-9.
33. Murayama A. Nine-Year Analysis of Industry Payments to Geriatricians in the United States Between 2014 and 2022. J Am Med Dir Assoc. 2023.
34. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in Industry Payments to Rheumatologists in the United States During the COVID-19 Pandemic Between 2013 and 2021. J Rheumatol. 2023;50(4):575-7.
35. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and Nonresearch Industry Payments to Nephrologists in the United States between 2014 and 2021. J Am Soc Nephrol. 2023;34(10):1709-20.
36. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States. CJC Open. 2023;5(3):253-5.
37. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A 9-Year Investigation of Healthcare Industry Payments to Pulmonologists in the United States. Ann Am Thorac Soc. 2023;20(9):1283-92.
38. Murayama A. A nine-year investigation of industry research and non-research payments to emergency physicians in the United States between 2014 and 2022. The Journal of Emergency Medicine. 2023.
39. Murayama A. Evaluation of Research and Non-research Industry Payments to Endocrinologists in the United States: An Analysis of the Open Payments Database from 2014 to 2022. Diabet Med. 2023:e15253.
40. Murayama A, Nakano K, Kamamoto S, Sato M, Saito H, Tanimoto T, Ozaki A. Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020. Clin Microbiol Infect. 2022;28(12):1655 e1- e4.
41. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol. 2022;129(5):635-6.
42. Ying X, Rosenblatt R, Fortune BE. Trends in Industry Payments to Gastroenterologists and Hepatologists in the United States From 2014 to 2020. Gastroenterology. 2022;163(4):787-91.
43. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry Payments to Physicians in the United States From 2014 to 2018. JAMA. 2020;324(17):1785-8.
44. Murayama A, Hirota S. Industry payments to pathologists in the USA between 2013 and 2021. J Clin Pathol. 2023;76(8):566-70.
45. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. Aust J Gen Pract. 2020;49(3):151-4.
46. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures. Intern Med J. 2021;51(11):1816-24.
47. Clinckemaillie M, Scanff A, Naudet F, Barbaroux A. Sunshine on KOLs: assessment of the nature, extent and evolution of financial ties between the leaders of professional medical associations and the pharmaceutical industry in France from 2014 to 2019: a retrospective study. BMJ Open. 2022;12(2):e051042.
48. Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S, Tomita K. Economic Burden of Alzheimer’s Disease Dementia in Japan. J Alzheimers Dis. 2021;81(1):309-19.
49. Nakahori N, Sekine M, Yamada M, Tatsuse T, Kido H, Suzuki M. Future projections of the prevalence of dementia in Japan: results from the Toyama Dementia Survey. BMC Geriatrics. 2021;21(1):602.
50. Japanese Society of Allergology. List of board-certified allergy specialists and advisors Online: Japanese Society of Allergology; 2022 [Available from:https://www.jsaweb.jp/modules/specialist/index.php?content_id=6.
51. Japan Pharmaceutical Manufacturers Association. Regarding the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions 2018 [Available from:https://www.jpma.or.jp/english/code/transparency_guideline/eki4g60000003klk-att/transparency_gl_intro_2018.pdf.
52. Medical Governance Research Institute, Tansa. Yen For Docs [Online database]. Medical Governance Research Institute; 2023 [updated September 11, 2023. Available from:https://yenfordocs.jp/.
53. Subramanian S. An Elementary Interpretation of the Gini Inequality Index. Theory and Decision. 2002;52(4):375-9.
54. Inoue K, Figueroa JF, Kondo N, Tsugawa Y. Changes in industry marketing payments to physicians during the covid-19 pandemic: quasi experimental, difference-in-difference study. BMJ Medicine. 2022;1(1):e000219.
55. Marcum ZA, Chang CY, Barthold D, Holmes HM, Lo-Ciganic WH. Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination. Neurol Clin Pract. 2021;11(3):181-7.
Table 1. Summary of personal payments to board-certified neurologists